Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Public ClinicalTrials.gov record NCT00112736. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.
Study identification
- NCT ID
- NCT00112736
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Conditions
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Oligodendroglioma
- Adult Diffuse Astrocytoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Pilocytic Astrocytoma
- Adult Pineal Gland Astrocytoma
- Adult Subependymal Giant Cell Astrocytoma
- Recurrent Adult Brain Tumor
Interventions
- erlotinib Drug
- temsirolimus Drug
- therapeutic conventional surgery Procedure
- laboratory biomarker analysis Other
- pharmacological study Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2005
- Primary completion
- Mar 31, 2010
- Completion
- Mar 31, 2014
- Last update posted
- Jun 14, 2015
2005 – 2014
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| University of California San Francisco | San Francisco | California | 94115 | — |
| National Cancer Institute Neuro-Oncology Branch | Bethesda | Maryland | 20814 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Texas Health Science Center | San Antonio | Texas | 78229 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00112736, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2015 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00112736 live on ClinicalTrials.gov.